SCYX
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trading near book value, but valuation is driven by growth expectations rather than current earnings.
- Price/Book near 1.0
- No P/E due to historical losses
- No Graham Number available
Growth metrics are astronomical, suggesting a product launch or market expansion phase.
- 1808% Revenue growth
- Positive EPS surprise trend
- Strong analyst targets
- Unproven long-term sustainability of growth
Long-term performance has been poor, though the last 12 months show a reversal.
- Recent 6-month price recovery (+47%)
- 5-year return of -85.1%
- Consistent history of earnings misses in early 2020s
The F-Score is a major red flag, but the balance sheet (liquidity/debt) is actually quite safe.
- Very low debt
- High current/quick ratios
- Piotroski F-Score of 1/9
- Negative ROE and ROA
Typical for growth-stage biotech companies.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SCYX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SCYX
SCYNEXIS, Inc.
Primary
|
-85.1% | -65.7% | +22.8% | +47.0% | +23.3% | +11.0% |
|
NTRB
Nutriband Inc.
Peer
|
-28.9% | +17.2% | -16.9% | -45.8% | +7.4% | +4.1% |
|
HYFT
MindWalk Holdings Corp.
Peer
|
-91.3% | -62.5% | +166.8% | -40.9% | -16.4% | -6.1% |
|
PETS
PetMed Express, Inc.
Peer
|
-91.2% | -84.4% | -23.0% | -7.9% | -8.2% | +1.3% |
|
ELUT
Elutia Inc.
Peer
|
-91.4% | -20.8% | -53.7% | +28.2% | -2.6% | +4.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SCYX
SCYNEXIS, Inc.
|
BULLISH | $49.58M | - | -16.5% | -41.8% | $1.11 | |
|
NTRB
Nutriband Inc.
|
BEARISH | $49.67M | - | -136.1% | -% | $4.08 | Compare |
|
HYFT
MindWalk Holdings Corp.
|
BEARISH | $49.98M | - | -58.8% | -43.6% | $1.07 | Compare |
|
PETS
PetMed Express, Inc.
|
BEARISH | $50.08M | - | -100.6% | -34.7% | $2.34 | Compare |
|
ELUT
Elutia Inc.
|
BULLISH | $48.77M | - | -% | 434.2% | $1.14 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | ANGULO GONZALEZ DAVID | Chief Executive Officer | Purchase | 108,695 | $96,554 |
| 2026-01-29 | ANGULO GONZALEZ DAVID | Chief Executive Officer | Stock Award | 391,333 | - |
| 2026-01-29 | SUKENICK SCOTT A. J.D. | Officer | Stock Award | 129,833 | - |
| 2026-01-29 | MACLEOD IVOR | Chief Financial Officer | Stock Award | 129,833 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SCYX from our newsroom.